Pioneering gene therapy trial fails to help girl, 2
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A REVOLUTIONARY operation that transplants genes to correct inherited defects and cancers has suffered a setback. The first gene therapy trial in Britain has failed to help a child with a rare genetic disorder of the immune system, writes Steve Connor.
Although Carly Todd, two, of Lennoxtown in Strathclyde, remains healthy, doctors at the Great Ormond Street Hospital in London cannot detect the gene they transplanted into her bone- marrow cells in March 1993.
Carly suffers a very rare deficiency of an enzyme - adenosine deaminase - that is vital for the immune system to function. Without treatment it leads to a build up of toxic substances in the blood.
Scientists took bone-marrow cells from Carly and infected them with a genetically engineered virus designed to transport a correct copy of the ADA gene into her cells. The bone marrow was then transplanted back into her body.
Dr Gareth Morgan, the consultant supervising the operation, said the initial results were promising. 'Analysis at two months showed the gene in the blood cells of the patient and at six months in the bone marrow but our latest analysis . . . does not show any evidence of the ADA gene,' he said.
Dr Morgan said Carly was healthy and living at home and there were no plans to repeat the gene therapy unless her condition deteriorated. Other gene therapy trials are planned by British doctors.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments